Early detection of prostate cancer: European Association of Urology recommendation.

[1]  S. Moss,et al.  Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. , 2013, European urology.

[2]  M. Baum.  Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? , 2013, European urology.

[3]  A. Tjønneland,et al.  Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. , 2013, European journal of cancer.

[4]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[5]  John W. Davis,et al.  Retracted: Many young men with prostate‐specific antigen (PSA) screen‐detected prostate cancers may be candidates for active surveillance , 2013, BJU international.

[6]  P. Scardino,et al.  Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study , 2013, BMJ : British Medical Journal.

[7]  Jennifer R. Rider,et al.  Natural history of early, localized prostate cancer: a final report from three decades of follow-up. , 2013, European urology.

[8]  T. Wilt,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[9]  Anssi Auvinen,et al.  Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). , 2012, European urology.

[10]  R. Conroy,et al.  The Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70 , 2012, ISRN oncology.

[11]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[12]  J. Carpten,et al.  Germline mutations in HOXB13 and prostate-cancer risk. , 2012, The New England journal of medicine.

[13]  Jonathan Izawa,et al.  Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Dirk F Moore,et al.  Impact of comorbidity on survival among men with localized prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Steyerberg,et al.  Prediction of prostate cancer in unscreened men: external validation of a risk calculator. , 2011, European journal of cancer.

[16]  P. Scardino,et al.  Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50 , 2011, Cancer.

[17]  J. Hugosson,et al.  The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial. , 2011, European journal of cancer.

[18]  M. Cooperberg,et al.  Impact of age at diagnosis on prostate cancer treatment and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Gavin,et al.  Balancing the harms and benefits of early detection of prostate cancer , 2010, Cancer.

[20]  Frederico Branco,et al.  Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. , 2010, European urology.

[21]  P. Scardino,et al.  Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study , 2010, BMJ : British Medical Journal.

[22]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[23]  Jianfeng Xu,et al.  Prostate cancer risk‐associated variants reported from genome‐wide association studies: Meta‐analysis and their contribution to genetic Variation , 2010, The Prostate.

[24]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[25]  J. Hugosson,et al.  Risk of dying from prostate cancer in men randomized to screening , 2009, Cancer.

[26]  Pär Stattin,et al.  Prostate specific antigen for early detection of prostate cancer: longitudinal study , 2009, BMJ : British Medical Journal.

[27]  U. Norming,et al.  15-year followup of a population based prostate cancer screening study. , 2009, The Journal of urology.

[28]  Seth Falcon,et al.  Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  J. Hugosson,et al.  Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. , 2007, European urology.

[30]  T. Wilt,et al.  Screening for prostate cancer: A Cochrane systematic review , 2007, Cancer Causes & Control.

[31]  Javier Hernandez,et al.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.

[32]  W. Catalona,et al.  Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. , 2006, Urology.

[33]  J. Hugosson,et al.  Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. , 2005, Archives of internal medicine.

[34]  D. Howard.  Life expectancy and the value of early detection. , 2005, Journal of health economics.

[35]  M. Roobol,et al.  Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). , 2005, Urology.

[36]  O. Löfman,et al.  Clinical consequences of screening for prostate cancer: 15 years follow-up of a randomised controlled trial in Sweden. , 2004, European urology.

[37]  W. Catalona,et al.  Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. , 2004, The Journal of urology.

[38]  F. Labrie,et al.  Screening decreases prostate cancer mortality: 11‐year follow‐up of the 1988 Quebec prospective randomized controlled trial , 2004, The Prostate.

[39]  Kazuto Ito,et al.  Possibility of re‐screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less , 2003, The Prostate.

[40]  J. Hugosson,et al.  Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. , 2003, The Journal of urology.

[41]  E. Metter,et al.  Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. , 2001, Urology.

[42]  A S Whittemore,et al.  Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.

[43]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[44]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[45]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[46]  Thomas Wiegel,et al.  Guidelines on Prostate Cancer , 2013 .

[47]  M. Roobol,et al.  Towards an optimal interval for prostate cancer screening. , 2012, European urology.

[48]  G. Andriole,et al.  Prostate-Cancer Mortality at 11 Years of Follow-up: Schröder FH, for the ERSPC Investigators (Erasmus Univ Med Ctr, Rotterdam, The Netherlands; et al) N Engl J Med 366:981-990, 2012 § , 2012 .

[49]  Ewout W Steyerberg,et al.  A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. , 2010, European urology.